Nyxoah Plans $70M+ IPO As It Starts IDE Trial For Neurostim Apnea Device
Belgian firm will float on Euronext Brussels; ResMed and Cochlear among existing investors who will invest in at least 25% of shares.
You may also be interested in...
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.
The market for devices to monitor and treat sleep apnea and its complications is set to grow by 7.3% annually in the next three years, with the US market expanding by 7.6% per year, according to the Meddevicetracker Dashboard.
The Oxford University spin-off has raised over £3m so far to develop its minimally invasive disc nucleus replacement technology and plans a £10m series A.